Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients

被引：23

作者：

Jakobsen, Jan Nyrop ^{[1
]}

Herrstedt, Jorn ^{[1
]}

机构：

[1] Odense Univ Hosp, Dept Oncol R, DK-5000 Odense C, Denmark

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2009年 / 71卷 / 03期

关键词：

Cancer; Chemotherapy; Nausea; Vomiting; Elderly; Antiemetics; RECEIVING END; OLDER PERSONS; PHARMACOKINETICS; ONCOLOGY; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; GRANISETRON; ONDANSETRON; ANTAGONISTS;

D O I：

10.1016/j.critrevonc.2008.12.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There is a global and continuing increase in the population of elderly people. This is particularly true among patients with cancer including those receiving chemotherapy. There are no guidelines that in particular address prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in the elderly. Elderly have a potential decreased risk of CINV due to the fact that they are often treated with less emetic chemotherapy and due to the fact that high age is protective. On the other hand, elderly have an increased risk of toxicity from antiemetics due to age-related decrease in organ function, use of poly-pharmacy with increased risk of drug-drug interactions and due to co-morbidity. Compliance needs to be carefully evaluated, particularly in patients with high risk of non-comphance, such as elderly with dementia and impaired vision. (c) 2009 Elsevier Ireland Ltd. All rights reserved.

引用

页码：214 / 221

页数：8

共 43 条

[1] Evaluation of the elderly with cancer [J].

Aapro, M ;

Extermann, M ;

Repetto, L .

ANNALS OF ONCOLOGY, 2000, 11 :223-229

[2] Chemotherapy-induced emesis in elderly cancer patients:: The role of 5-HT3-receptor antagonists in the first 24 hours [J].

Aapro, M ;

Johnson, J .

GERONTOLOGY, 2005, 51 (05) :287-296

[3] EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours [J].

Aapro, M. S. ;

Cameron, D. A. ;

Pettengell, R. ;

Bohlius, J. ;

Crawford, J. ;

Ellis, M. ;

Kearney, N. ;

Lyman, G. H. ;

Tjan-Heijnen, V. C. ;

Walewski, J. ;

Weber, D. C. ;

Zielinski, C. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) :2433-2453

[4] DEVELOPMENT OF ANTICIPATORY NAUSEA - A PROSPECTIVE ANALYSIS [J].

ANDRYKOWSKI, MA ;

REDD, WH ;

HATFIELD, AK .

JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1985, 53 (04) :447-454

[5]

Banning Maggi, 2004, Br J Nurs, V13, P669

[6] Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment [J].

Bloechl-Daum, Brigitte ;

Deuson, Robert R. ;

Mavros, Panagiotis ;

Hansen, Mogens ;

Herrstedt, Jorn .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4472-4478

[7] Drug-drug interactions in oncology: Why are they important and can they be minimized? [J].

Blower, P ;

de Wit, R ;

Goodin, S ;

Aapro, M .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 55 (02) :117-142

[8] Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects [J].

Blum, RA ;

Majumdar, A ;

McCrea, J ;

Busillo, J ;

Orlowski, LH ;

Panebianco, D ;

Hesney, M ;

Petty, KJ ;

Goldberg, MR ;

Murphy, MG ;

Gottesdiener, KM ;

Hustad, CM ;

Lates, C ;

Kraft, WK ;

Van Buren, S ;

Waldman, SA ;

Greenberg, HE .

CLINICAL THERAPEUTICS, 2003, 25 (05) :1407-1419

[9] The globalisation of cancer [J].

Boyle, Peter .

LANCET, 2006, 368 (9536) :629-630

[10]

BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104

← 1 2 3 4 5 →